The global BPH treatment market revenue is expected to be $18,837.7 million in 2030, exhibiting a compound annual growth rate of 5.2% during 2021–2030. This can be attributed to the growing geriatric population and rising awareness of the BPH disorder.
The increasing prevalence of this disease is the biggest factor driving the market. In turn, one of the factors contributing to the rising prevalence of this problem is the changing lifestyle. Despite the variable patterns, there are some signs that food products play a role in the risk of BPH. For instance, it has been found that red meat, fat, milk and other dairy products, cereals, bread, poultry, and starch all potentially increase the risk of clinical BPH, whereas vegetables, fruits, polyunsaturated fatty acids, linoleic acid, and vitamin D potentially decrease this risk.
Similarly, higher circulation levels of micronutrients such as vitamin E, lycopene, selenium, and carotene have been found to be negatively related to BPH. Moreover, the reduced physical activity and exercise have been consistently associated with a higher risk of clinical BPH, histological BPH, and lower urinary tract symptoms (LUTS). A sedentary lifestyle is also increasing the prevalence of the condition. According to a meta-analysis of 11 published studies, compared to a sedentary lifestyle, moderate-to-vigorous physical activity lowers the risk of the disease by up to 25%, with the protective impact increasing with higher levels of activity.
Among the treatment types, drugs led the BPH treatment market in 2021, and they are expected to register the higher CAGR during the forecast period. This is due to the surging consumption of alpha-blockers, including tamsulosin, doxazosin, alfuzosin, and silodosin, for the treatment. Moreover, the demand for 5-alpha reductase inhibitors, including finasteride and dutasteride, is expected to increase in the long run.
Geographically, North America dominated the market in 2021, with revenue of around $5 billion. The regional market is projected to maintain its dominance in the coming years due to the booming elderly population, unhealthy lifestyles giving rise to obesity among men, presence of key players, and increase in the R&D activities to develop new products.
Europe is expected to record the second-fastest growth during the forecast period. This growth can be attributed to the escalating prevalence of chronic diseases, such as BPH, due to the changing lifestyles. This increasing patient population and use of advanced devices to treat them stimulate the regional market growth.
Additionally, the region, particularly Western Europe, has a robust healthcare infrastructure, and people have access to advanced healthcare services, including treatments for BPH. For instance, BPH is strongly age-related and the most-common urological disease in men in Germany. Around 20% of the men between the ages of 50 and 59 are affected. Furthermore, for men above 70 years of age, the probability increases to 70%, while 90% of the people above the age of 80 suffer from this disease.
Key players in the market include Sanofi, Pfizer Inc., Astellas Pharma Inc., Allergan plc, Teleflex Incorporated, Boston Scientific Corporation, IPG Photonics Corporation, and Olympus Corporation.